Smart Bilayer Tablets with Integrated Technologies

Publication ID: 24-11857684_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Smart Bilayer Tablets with Integrated Technologies,” Published Technical Disclosure No. 24-11857684_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857684_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,684.

Summary of the Inventive Concept

The present inventive concept integrates bilayer tablets comprising acetylsalicylic acid and pseudoephedrine with cutting-edge technologies, such as AI, IoT, blockchain, and novel materials, to create a more powerful system for personalized medicine and optimized storage conditions.

Background and Problem Solved

The original patent disclosed bilayer tablets with improved dissolution properties, but limitations in terms of real-time monitoring, personalized dosing, and optimized storage conditions remained. The present inventive concept addresses these limitations by synergistically combining the patented bilayer tablets with distinct technologies.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for monitoring and optimizing the storage conditions of bilayer tablets using IoT-enabled sensors and blockchain-based data storage. Additionally, AI-powered predictive analytics enable personalized dosing regimens based on individual patient characteristics. The tablets can be fabricated using 3D printing technology and incorporate novel materials with enhanced dissolution properties. A microfluidic device simulates in-vivo conditions, and a sensor array detects changes in tablet dissolution, predicting therapeutic efficacy. The inventive concept also includes a method for optimizing the formulation of bilayer tablets using AI-driven molecular modeling and IoT-enabled sensors.

Novelty and Inventive Step

The new claims introduce novel combinations of technologies, such as AI, IoT, blockchain, and novel materials, which are not obvious from the original patent. The inventive concept's integration of these technologies with the patented bilayer tablets provides a non-obvious solution to the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of other machine learning algorithms, different IoT-enabled sensors, or alternative blockchain-based data storage systems. Variations of the inventive concept could also incorporate other active pharmaceutical ingredients or different dissolution aids.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine, real-time monitoring, and optimized storage conditions. Target industries include pharmaceutical manufacturers, healthcare providers, and medical research institutions.

CPC Classifications

Section	Class	Group
A	A61	A61K9/209
A	A61	A61J3/10
A	A61	A61K31/137
A	A61	A61K31/616
A	A61	A61K9/2009
A	A61	A61K9/2018
A	A61	A61K9/2054
A	A61	A61K9/2059

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical formulation and drug delivery systems, with specialized expertise in bilayer tablet design, pharmaceutical manufacturing, and advanced drug delivery technologies

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or engineer with advanced degree (MS/PhD) in pharmaceutical sciences, expertise in tablet formulation, knowledge of excipient interactions, manufacturing processes, and emerging drug delivery technologies

Obviousness Rationale

A PHOSITA would recognize that integrating digital monitoring and personalization technologies with existing pharmaceutical formulation techniques represents a predictable extension of current pharmaceutical research trends. The core bilayer tablet structure remains fundamentally unchanged, with technological additions providing enhanced monitoring and customization capabilities. The proposed variations leverage well-established technological domains like IoT, AI, and 3D printing to address known challenges in pharmaceutical manufacturing and patient-specific drug delivery.

Obvious Combinations & Variations

Source Patent Element

Bilayer tablet with specific acetylsalicylic acid and sodium carbonate granulation techniques

PTD Variation

3D printing fabrication of bilayer tablets with enhanced dissolution properties

Obviousness Reasoning

Manufacturing technique evolution is a predictable progression for pharmaceutical formulation, with 3D printing representing a known advanced manufacturing technique for precise drug delivery systems

Source Patent Element

Pharmaceutical tablet with defined active ingredient composition

PTD Variation

IoT-enabled sensor monitoring of tablet storage conditions and degradation rates

Obviousness Reasoning

Monitoring pharmaceutical product stability is a standard industry practice, and integrating digital sensors represents an obvious technological enhancement for quality control

Source Patent Element

Bilayer tablet with specific pharmaceutical ingredients

PTD Variation

AI-powered predictive analytics for personalized dosing regimens

Obviousness Reasoning

Personalized medicine approaches are an emerging trend, and applying machine learning to pharmaceutical dosing represents a logical extension of existing clinical research methodologies

Source Patent Element

Pharmaceutical tablet formulation with defined excipient interactions

PTD Variation

Microfluidic device simulating in-vivo dissolution conditions with sensor array

Obviousness Reasoning

Advanced dissolution testing methodologies are well-established in pharmaceutical research, and combining microfluidic technologies with sensor monitoring represents a predictable technological progression

Source Patent Element

Pharmaceutical tablet with defined ingredient ratios

PTD Variation

Blockchain-based data storage for tracking tablet manufacturing and patient history

Obviousness Reasoning

Pharmaceutical traceability and data management are critical industry concerns, and blockchain represents a known technological solution for enhanced record-keeping and authentication

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857684 and the published technical disclosure, a person of ordinary skill in the art would find the proposed technological variations obvious and predictable extensions of existing pharmaceutical formulation and digital monitoring techniques. The integration of IoT, AI, blockchain, and advanced manufacturing technologies with established bilayer tablet design represents a logical and non-inventive progression in pharmaceutical research and development.

Original Patent Information

Patent Number	US 11,857,684
Title	Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
Assignee(s)	BAYER AKTIENGESELLSCHAFT